.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Prostate cancer remains a leading cause of cancer-related mortality globally. Its development heavily depends on androgen receptor (AR) signaling. Consequently, initial treatments effectively target this pathway using androgen-deprivation therapy. However, many patients eventually face Advanced Prostate Cancer progression. This lethal stage, known as castration-resistant prostate cancer (CRPC), often evolves through the reactivation of AR signaling. Additionally, some tumors adopt new identities to survive and bypass current medications.
Lineage plasticity allows cancer cells to transform and escape the effects of standard therapies. For instance, neuroendocrine prostate cancer (NEPC) arises when cells lose their luminal epithelial identity. Moreover, another aggressive subtype, double-negative prostate cancer (DNPC), lacks both AR and neuroendocrine markers. Because of these biological shifts, the disease becomes extremely difficult to treat with conventional inhibitors.
Recent high-resolution investigations reveal that the three-dimensional (3D) genome architecture is vital for controlling these complex lineage states. Specifically, chromatin modifications and structural alterations directly influence gene regulation. Furthermore, specific enhancer-promoter communications drive the expression of transcriptional regulators that maintain cancer cell identity. Consequently, these 3D changes offer new insights into how tumors develop resistance to hormone therapies. Therefore, researchers now view these architectural vulnerabilities as potential targets for next-generation medicine. Ultimately, understanding these mechanisms is essential for improving clinical outcomes in metastatic cases.
Lineage plasticity refers to the ability of cancer cells to change their cellular identity. This process allows them to shift from an AR-dependent state to AR-independent states like NEPC, effectively bypassing hormone-based treatments.
The 3D genome architecture organizes DNA within the nucleus to control gene expression. In advanced cancer, changes in this structure can activate oncogenes or silence tumor suppressors, facilitating rapid disease progression and treatment resistance.
Treatments for CRPC often fail because the cancer adapts by either reactivating the androgen receptor pathway or evolving into different lineages that no longer require androgen signaling for growth.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Qi S et al. 3D Genome Architecture and Epigenetic Regulation of Lineage Identity in Advanced Prostate Cancer. Endocrinology. 2026 Jun 17. doi: undefined. PMID: 42306870.
2. Campbell EM, et al. Interplay of the 3D genome and epigenome in androgen-driven prostate cancer. Epigenomics. 2026 May 22. doi: 10.1080/17501911.2026.2676129.
3. Beltran H, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016. doi: 10.1038/nm.4045.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This research explores how 3D genome architecture and epigenetic regulation control lineage identity in advanced prostate cancer, offering new insights into treatment resistance and potential therapeutic targets for castration-resistant and neuroendocrine phenotypes.
4 months ago
Depemokimab offers twice-yearly dosing for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, significantly cutting exacerbations and hospital admissions.
3 days back
A novel copper metal-organic framework hydrogel remodels the uterine microenvironment to stimulate robust endometrial regeneration, reduce intrauterine fibrosis, and restore reproductive fertility, offering a groundbreaking strategy for managing refractory endometrial damage and Asherman syndrome.
4 days back
New research reveals that non-ablative radiotherapy suppresses ventricular tachycardia by increasing conduction velocity via NaV1.5 upregulation and action potential prolongation. However, sustained sodium current elevation and depressed calcium handling highlight the need for careful clinical translation.
6 days back
A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
4 days back
A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
4 days back
